Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort,
dose finding study to assess the safety and efficacy of eltrombopag in patients with solid
tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin
or cisplatin. Phase I of the study will examine safety and tolerability of various doses of
eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the
chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful
benefit(s) to thrombocytopenic patients by improving platelet numbers.